Financings
Apolo V files filing statement for QT
TelyRx QT Filing Clears Final Hurdles as Financing Target Slashes to $20M

Executive Summary
- Apolo V Acquisition Corp. filed a formal filing statement on March 25, 2026, detailing its proposed Qualifying Transaction (QT) with TelyRx Inc. and related entities.
- The transaction is structured as a reverse takeover, with TelyRx as the surviving entity. The combined company will list on the Toronto Stock Exchange under the ticker TELY.
- A concurrent private placement via TelyRx Finco Inc. is structured as a best-efforts offering of 6,091,111 to 9,136,666 subscription receipts at $4.50 each, targeting gross proceeds of US$20 million (minimum) to US$30 million (maximum).
- Both the TSX-V and TSX have granted conditional approvals. The transaction is expected to close on or around March 31, 2026, at which point trading of Apolo V shares will resume under the new ticker.
- This filing follows the March 6, 2026 shareholder approval meeting, where all resolutions passed with 98.6% to 100% support.
Material Impact
- The filing is a procedural, expected milestone that removes the final administrative hurdle before closing. It does not introduce new operational or financial data.
- The most notable deviation from prior announcements is the reduction in the private placement target from the originally pitched US$40 million to US$46 million down to a US$20 million to US$30 million range. This signals either constrained institutional appetite, a recalibrated capital requirement, or both.
- Given the company's negative equity position and high liability load, the smaller raise tightens the post-merger financial runway. The impact is incrementally positive for deal certainty but materially neutral regarding fundamental risk reduction.
AFV · Price
Company Overview
- Apolo V is a Capital Pool Company (CPC) shell executing a reverse takeover with TelyRx Inc., a digital health platform focused on streamlining prescription medication access through telehealth and e-pharmacy services.
- The flagship project is the TelyRx commercial platform, which generated US$28.61 million in revenue over the nine months ended September 30, 2025.
- Despite top-line traction, the platform remains unprofitable, reporting a net loss of US$2.33 million for the same period. The business model relies on scaling user acquisition while managing high operational and regulatory overhead.
More from Apolo V Acquisition Corp
Mar 06, 2026 · 09:09